Trial Profile
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Darvadstrocel (Primary)
- Indications Rectal fistula
- Focus Registrational; Therapeutic Use
- Sponsors Takeda; Takeda Development Center Americas
- 18 Aug 2023 Planned End Date changed from 15 Jan 2024 to 31 Dec 2025.
- 18 Aug 2023 Planned primary completion date changed from 15 Jul 2023 to 30 Jun 2025.
- 12 Jul 2021 Status changed from not yet recruiting to recruiting.